{"groups":[{"description":"Cetuximab beginning weekly dose 400 mg/m\\^2 intravenous (IV), and 250 mg/m\\^2 weeks 2-6; Weekly Carboplatin Area Under the Curve (AUC) 2 and Paclitaxel 135 mg/m\\^2 for 6 courses.","id":"FG000","title":"Cetuximab + Carboplatin/Paclitaxel"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"47"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"47"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Of the forty-eight (48) participants registered, forty-seven (47) were eligible to participate in this trial","recruitmentDetails":"Recruitment Period: January 31, 2005 to September 16, 2011"}